Andreas Lundqvist

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Professor, Karolinska Institutet, Institutionen för Onkologi-Patologi, 2023

Docent, Karolinska Institutet, 2012
Forskare, National Institutes of Health, 2008
Postdoktoral utbildning, National Institutes of Health, 2003
PhD, Karolinska Institutet, 2003

Forskningsbeskrivning

Vår forskning fokuserar på att förstå hur immunförsvaret regleras hos patienter med cancer.

Undervisning

Genomgått 10 veckor utbildning i pedagogik.
Kursorganisatör för doktorandkurs i tumörimmunologi (#3110), Karolinska Institutet.

Artiklar

Article: ONCOIMMUNOLOGY. 2024;13(1):2372875
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden
Hamida O; Karlsson F; Lundqvist A; Gerling M; Liu LL
Article: SCIENCE TRANSLATIONAL MEDICINE. 2024;16(747):eadi2952
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis
Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickstrom SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
Article: JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH. 2024;43(1):107
A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells
Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Gondor A; Ostling P; Holmgren L
Article: JOURNAL OF EXPERIMENTAL AND CLINICAL CANCER RESEARCH. 2024;43(1):13
Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease
Neo SY; Oliveira MMS; Tong L; Chen Y; Chen Z; Cismas S; Burduli N; Malmerfelt A; Teo JKH; Lam K-P; Alici E; Girnita L; Wagner AK; Westerberg LS; Lundqvist A
Article: ONCOIMMUNOLOGY. 2023;12(1):2175517
CD25^bright NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression
Chen Z; Tong L; Neo SY; Li S; Gao J; Schlisio S; Lundqvist A
Article: CELLS. 2023;12(17):2158
Deciphering the Role of p60AmotL2 in Epithelial Extrusion and Cell Detachment
Cui W; Subramani A; Fonseca P; Zhang Y; Tong L; Zhang Y; Egevad L; Lundqvist A; Holmgren L
Article: CYTOTHERAPY. 2023;25(7):763-772
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide
Karvouni M; Vidal-Manrique M; Susek KH; Hussain A; Gilljam M; Zhang Y; Gray JD; Lund J; Kaufmann G; Ljunggren H-G; Ji H; Lundqvist A; Wagner AK; Guo W; Alici E
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2023;72(5):1153-1167
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner AK; Alici E
Article: CANCER IMMUNOLOGY RESEARCH. 2023;11(2):217-227
Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Veerman RE; Akpinar GG; Offens A; Steiner L; Larssen P; Lundqvist A; Karlsson MCI; Gabrielsson S
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(1):e2209856120
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction
Chen X; Sifakis EG; Robertson S; Neo SY; Jun S-H; Tong L; Min ATH; Lovrot J; Hellgren R; Margolin S; Bergh J; Foukakis T; Lagergren J; Lundqvist A; Ma R; Hartman J
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1264012
Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma
Tay AHM; Cinotti R; Sze NSK; Lundqvist A
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(10):e005308
Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells
Neo SY; Jing X; Tong L; Tong D; Gao J; Chen Z; De Los Santos MC; Burduli N; Ferreira SDS; Wagner AK; Alici E; Rolny C; Cao Y; Lundqvist A
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(6):e004458
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
Renken S; Nakajima T; Magalhaes I; Mattsson J; Lundqvist A; Arner ESJ; Kiessling R; Wickstrom SL
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2022;10(5):e004592
A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
Tay AHM; Prieto-Diaz R; Neo S; Tong L; Chen X; Carannante V; Onfelt B; Hartman J; Haglund F; Majellaro M; Azuaje J; Garcia-Mera X; Brea JM; Loza MI; Jespers W; Gutierrez-de-Teran H; Sotelo E; Lundqvist A
Article: NATURE CANCER. 2022;3(2):251-261
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
Tamborero D; Dienstmann R; Rachid MH; Boekel J; Lopez-Fernandez A; Jonsson M; Razzak A; Brana I; De Petris L; Yachnin J; Baird RD; Loriot Y; Massard C; Martin-Romano P; Opdam F; Schlenk RF; Vernieri C; Masucci M; Villalobos X; Chavarria E; Balmana J; Apolone G; Caldas C; Bergh J; Ernberg I; Frohling S; Garralda E; Karlsson C; Tabernero J; Voest E; Rodon J; Lehtio J
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2021;70(11):3155-3166
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
Witt K; Evans-Axelsson S; Lundqvist A; Johansson M; Bjartell A; Hellsten R
Article: ADVANCED SCIENCE. 2021;8(21):e2101029
Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism
Wu J; Chen Z; Wickstrom SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y
Article: CANCERS. 2021;13(5):1175
CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma
Su Y; Tsagkozis P; Papakonstantinou A; Tobin NP; Gultekin O; Malmerfelt A; Ingelshed K; Neo SY; Lundquist J; Chaabane W; Nisancioglu MH; Leiss LW; Ostman A; Bergh J; Sedimbi S; Lehti K; Lundqvist A; Stragliotto CL; Haglund F; Ehnman M
Article: EMBO REPORTS. 2021;22(3):e51329
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25⁺/CD54⁺ NK cells
Chen Z; Yang Y; Neo SY; Shi H; Chen Y; Wagner AK; Larsson K; Tong L; Jakobsson P-J; Alici E; Wu J; Cao Y; Wang K; Liu LL; Mao Y; Sarhan D; Lundqvist A
Article: CELLS. 2021;10(2):353
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
Luu K; Patwardhan MV; Zeng Q; Wickstrom SL; Lundqvist A; Schwarz H
Article: FRONTIERS IN IMMUNOLOGY. 2021;12:682627
B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion
Luu K; Schwarz H; Lundqvist A
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(10):5508-5522
Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells
Yang Y; Neo SY; Chen Z; Cui W; Chen Y; Guo M; Wang Y; Xu H; Kurzay A; Alici E; Holmgren L; Haglund F; Wang K; Lundqvist A
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(37):22910-22919
Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo
He X; Yin X; Wu J; Wickstrom SL; Duo Y; Du Q; Qin S; Yao S; Jing X; Hosaka K; Wu J; Jensen LD; Lundqvist A; Salter AI; Brautigam L; Tao W; Chen Y; Kiessling R; Cao Y
Article: ONCOIMMUNOLOGY. 2020;9(1):1786888
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
de Coana YP; Wolodarski M; Avila IVDH; Nakajima T; Rentouli S; Lundqvist A; Masucci G; Hansson J; Kiessling R
Article: ONCOIMMUNOLOGY. 2020;9(1):1792058
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Lovgren T; Wolodarski M; Wickstrom S; Edback U; Wallin M; Martell E; Markland K; Blomberg P; Nystrom M; Lundqvist A; Jacobsson H; Ullenhag G; Ljungman P; Hansson J; Masucci G; Tell R; Poschke I; Adamson L; Mattsson J; Kiessling R
Article: JOURNAL OF CLINICAL INVESTIGATION. 2020;130(3):1185-1198
CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
Article: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 2020;1296:319-348
Sarcoma Tumor Microenvironment
Tsagozis P; Gonzalez-Molina J; Georgoudaki A-M; Lehti K; Carlson J; Lundqvist A; Haglund F; Ehnman M
Article: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 2020;1231:45-51
The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment
Neo SY; Lundqvist A
Article: SCIENTIFIC REPORTS. 2019;9(1):12150
Exhaustion of CD4+T-cells mediated by the Kynurenine Pathway in Melanoma
Pour SR; Morikawa H; Kiani N; Yang M; Azimi A; Shafi G; Shang M; Baumgartner R; Ketelhuth DFJ; Kamleh MA; Wheelock CE; Lundqvist A; Hansson J; Tegner J
Article: METHODS IN MOLECULAR BIOLOGY. 2019;1913:197-206
Evaluation of Breast Cancer and Melanoma Metastasis in Syngeneic Mouse Models.
Witt K; Lundqvist A
Article: METHODS IN MOLECULAR BIOLOGY. 2019;2032:105-114
Strategies and Techniques for NK Cell Phenotyping.
Ziqing C; Lundqvist A; Witt K
Article: CANCER IMMUNOLOGY RESEARCH. 2018;6(11):1417-1425
Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma
Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Wallmann T; Tufvesson-Stiller H; Chambers BJ; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Article: LAB ON A CHIP. 2018;18(16):2466-2476
Acoustic formation of multicellular tumor spheroids enabling on-chip functional and structural imaging
Olofsson K; Carannante V; Ohlin M; Frisk T; Kushiro K; Takai M; Lundqvist A; Onfelt B; Wiklund M
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2017;66(10):1333-1344
Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists
Lovgren T; Sarhan D; Truxova I; Choudhary B; Maas R; Melief J; Nystrom M; Edback U; Vermeij R; Scurti G; Nishimura M; Masucci G; Karlsson-Parra A; Lundqvist A; Adamson L; Kiessling R
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2017;5(1):73
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma
Kremer V; Ligtenberg M; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colon E; Scherman-Plogell A-H; Lundqvist A
Article: ONCOIMMUNOLOGY. 2017;6(8):e1338238
Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer
Sarhan D; Leijonhufvud C; Murray S; Witt K; Seitz C; Wallerius M; Xie H; Ullen A; Harmenberg U; Lidbrink E; Rolny C; Andersson J; Lundqvist A
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: BLOOD. 2016;128(11):1475-1489
IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells
Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Article: ONCOIMMUNOLOGY. 2016;5(5):e1128613
Cripto-1 vaccination elicits protective immunity against metastatic melanoma
Ligtenberg MA; Witt K; Galvez-Cancino F; Sette A; Lundqvist A; Lladser A; Kiessling R
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2016;12(3):607-611
Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience
Murray S; Lundqvist A
Article: ONCOIMMUNOLOGY. 2016;5(1):e1052213
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis
Andersson E; Poschke I; Villabona L; Carlson JW; Lundqvist A; Kiessling R; Seliger B; Masucci GV
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793
Dendritic cell regulation of NK-cell responses involves lymphotoxin-, IL-12, and TGF-
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2015;64(2):225-235
CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo
Wennerberg E; Kremer V; Childs R; Lundqvist A
Article: PLOS ONE. 2015;10(10):e0139809
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
Article: CLINICAL CANCER RESEARCH. 2014;20(22):5733-5744
Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell-Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
Wennerberg E; Pfefferle A; Ekblad L; Yoshimoto Y; Kremer V; Kaminskyy VO; Juhlin CC; Hoog A; Bodin I; Svjatoha V; Larsson C; Zedenius J; Wennerberg J; Lundqvist A
Article: CLINICAL CANCER RESEARCH. 2014;20(15):4096-4106
Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Article: IMMUNOBIOLOGY. 2014;219(3):189-197
Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients
Gonzalez FE; Ramirez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Saazar-Onfray F
Article: JOURNAL OF IMMUNOLOGY. 2014;192(3):1313-1319
Gap Junction Intercellular Communications Regulate NK Cell Activation and Modulate NK Cytotoxic Capacity
Tittarelli A; Mendoza-Naranjo A; Farias M; Guerrero I; Ihara F; Wennerberg E; Riquelme S; Gleisner A; Kalergis A; Lundqvist A; Lopez MN; Chambers BJ; Salazar-Onfray F
Article: JOURNAL OF IMMUNOLOGY. 2013;191(12):6241-6249
Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF
Lundqvist A; Smith AL; Takahashi Y; Wong S; Bahceci E; Cook L; Ramos C; Tawab A; McCoy JPJ; Read EJ; Khuu HM; Bolan CD; Joo J; Geller N; Leitman SF; Calandra G; Dunbar C; Kurlander R; Childs RW
Article: INTERNATIONAL JOURNAL OF CANCER. 2013;133(7):1643-1652
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
Wennerberg E; Sarhan D; Carlsten M; Kaminskyy VO; D'Arcy P; Zhivotovsky B; Childs R; Lundqvist A
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2013;62(8):1359-1368
A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
Sarhan D; Wennerberg E; D'Arcy P; Gurajada D; Linder S; Lundqvist A
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2013;43(1):249-257
Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
Sarhan D; D'Arcy P; Wennerberg E; Lidén M; Hu J; Winqvist O; Rolny C; Lundqvist A
Article: JOURNAL OF IMMUNOLOGY. 2012;188(5):2136-2145
HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
Article: CYTOTHERAPY. 2011;13(3):269-278
Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways
Gotherstrom C; Lundqvist A; Duprez IR; Childs R; Berg L; le Blanc K
Article: JOURNAL OF CANCER. 2011;2:383-385
Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
Lundqvist A; Berg M; Smith A; Childs RW
Article: STEM CELLS. 2010;28(9):1465-1475
Major Histocompatibility Complex-I Expression on Embryonic Stem Cell-Derived Vascular Progenitor Cells Is Critical for Syngeneic Transplant Survival
Ma M; Ding S; Lundqvist A; San H; Fang F; Konoplyannikov M; Berry C; Beltran LE; Chen G; Kovacic JC; Boehm M
Article: JOURNAL OF IMMUNOLOGY. 2010;184(3):1139-1142
Cutting Edge: Bortezomib-Treated Tumors Sensitized to NK Cell Apoptosis Paradoxically Acquire Resistance to Antigen-Specific T Cells
Lundqvist A; Su S; Rao S; Childs R
Article: BLOOD. 2009;113(24):6120-6127
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
Article: BLOOD. 2009;113(4):875-882
Primitive quiescent CD34⁺ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
Yong ASM; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
Article: CYTOTHERAPY. 2009;11(3):341-355
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
Berg M; Lundqvist A; McCoy PJ; Samsel L; Fan Y; Tawab A; Childs R
Article: JOURNAL OF CLINICAL INVESTIGATION. 2008;118(3):1099-1109
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells
Takahashi Y; Harashima N; Kajigaya S; Yokoyama H; Cherkasova E; McCoy JP; Hanada K-I; Mena O; Kurlander R; Abdul T; Srinivasan R; Lundqvist A; Malinzak E; Geller N; Lerman MI; Childs RW
Article: CYTOTHERAPY. 2008;10(8):775-783
Natural killer cell immunotherapy for cancer: a new hope
Srivastava S; Lundqvist A; Childs RW
Article: BLOOD. 2007;109(8):3603-3606
Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors
Lundqvist A; McCoy JP; Samsel L; Childs R
Article: CANCER RESEARCH. 2006;66(14):7317-7325
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Article: EXPERIMENTAL HEMATOLOGY. 2006;34(6):796-801
Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
Srinivasan R; Daniels J; Fusaro V; Lundqvist A; Killian JK; Geho D; Quezado M; Kleiner D; Rucker S; Espinac V; Whiteley G; Liotta L; Petricoin E; Pittaluga S; Hitt B; Barrett AJ; Rosenblatt K; Childs RW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;133(3):305-314
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation
Srinivasan R; Takahashi Y; McCoy JP; Espinoza-Delgado I; Dorrance C; Igarashi T; Lundqvist A; Barrett AJ; Young NS; Geller N; Childs RW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2005;131(1):74-79
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation
Srinivasan R; Balow JE; Sabnis S; Lundqvist A; Igarashi T; Takahashi Y; Austin H; Tisdale J; Barrett J; Geller N; Childs R
Article: THE LANCET ONCOLOGY. 2005;6(10):809-812
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib
Savani BN; Srinivasan R; Espinoza-Delgado I; Dorrance C; Takahashi Y; Igarashi T; Rezvani K; Lundqvist A; Barrett AJ; Childs RW
Article: IMMUNOLOGY LETTERS. 2005;100(2):113-119
Effects of human plasma proteins on maturation of monocyte-derived dendritic cells
Tobiásová-Czetoová Z; Palmborg A; Lundqvist A; Karlsson G; Adamson L; Bartunková J; Masucci G; Pisa P
Article: JOURNAL OF IMMUNOTHERAPY. 2005;28(3):229-235
Mature dendritic cells induce tumor-specific type 1 regulatory T cells
Lundqvist A; Palmborg A; Pavlenko M; Levitskaya D; Pisa P
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2005;128(5):668-675
Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation
Griffith LM; McCoy JP; Bolan CD; Stroncek DF; Pickett AC; Linton GF; Lundqvist A; Srinivasan R; Leitman SF; Childs RW
Article: BRITISH JOURNAL OF CANCER. 2004;91(4):688-694
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer
Pavlenko M; Roos AK; Lundqvist A; Palmborg A; Miller AM; Ozenci V; Bergman B; Egevad L; Hellström M; Kiessling R; Masucci G; Wersäll P; Nilsson S; Pisa P
Article: MEDICAL ONCOLOGY. 2004;21(1):49-52
Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates
De Petris L; Bergfeldt K; Hising C; Lundqvist A; Tholander B; Pisa P; van der Zanden HGM; Masucci G
Article: MEDICAL ONCOLOGY. 2004;21(2):155-165
Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses
Lundqvist A; Palmborg A; Bidla G; Whelan M; Pandha W; Pisa P
Article: CYTOTHERAPY. 2004;6(4):363-371
Development of a technology platform for large-scale clinical grade production of DC
Adamson L; Palmborg A; Svensson A; Lundqvist A; Hansson M; Kiessling R; Masucci G; Mellstedt H; Pisa P
Article: JOURNAL OF IMMUNOTHERAPY. 2002;25(6):445-454
Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection
Lundqvist A; Noffz G; Pavlenko M; Sæboe-Larssen S; Fong T; Maitland N; Pisa P
Article: HUMAN GENE THERAPY. 2002;13(13):1541-1549
Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis
Lundqvist A; Choudhury A; Nagata T; Andersson T; Quinn G; Fong T; Maitland N; Pettersson S; Paulie S; Pisa P
Article: BRITISH JOURNAL OF CANCER. 2002;87(4):414-422
Tissue distribution and differential expression of melanocortin I receptor, a malignant melanoma marker
Salazar-Onfray F; López M; Lundqvist A; Aguirre A; Escobar A; Serrano A; Korenblit C; Petersson M; Chhajlani V; Larsson O; Kiessling R
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2002;51(3):139-144
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X_L
Lundqvist A; Nagata T; Kiessling R; Pisa P
Visa fler

Alla övriga publikationer

Review: MED. 2024;5(11):1351-1377
Patient-derived organoids in precision cancer medicine
Tong L; Cui W; Zhang B; Fonseca P; Zhao Q; Zhang P; Xu B; Zhang Q; Li Z; Seashore-Ludlow B; Yang Y; Si L; Lundqvist A
Editorial comment: NATURE REVIEWS IMMUNOLOGY. 2023;23(8):478
Pannexin 1 regulates CD8⁺ T cell function and memory formation
De Los Santos MC; Lundqvist A
Letter: CANCER COMMUNICATIONS. 2023;43(7):855-859
Renal cell carcinoma escapes NK cell-mediated immune surveillance through the downregulation of DNAM-1
Tong L; Kremer V; Neo SY; Liu Y; Chen Y; Wagner AK; Yang Y; Chen Z; Seitz C; Tobin NP; Ligtenberg MA; Alici E; Chen X; Haglund F; Seliger B; Harmenberg U; Colon E; Plogell A-HS; Liu LL; Lundqvist A
Review: MOLECULAR CANCER. 2022;21(1):206
NK cells and solid tumors: therapeutic potential and persisting obstacles
Tong L; Jimenez-Cortegana C; Tay AHM; Wickstrom S; Galluzzi L; Lundqvist A
Review: FRONTIERS IN IMMUNOLOGY. 2022;13:825979
Engineered NK Cells Against Cancer and Their Potential Applications Beyond
Karvouni M; Vidal-Manrique M; Lundqvist A; Alici E
Editorial comment: FRONTIERS IN IMMUNOLOGY. 2021;12:718844
Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
Wennerberg E; Lundqvist A; Mao Y; Mougiakakos D
Review: CANCERS. 2020;12(12):E3586-3586
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
Yang Y; Lundqvist A
Review: PHARMACOLOGY AND THERAPEUTICS. 2020;214:107603
Genetically modified immune cells targeting tumor antigens
Poorebrahim M; Abazari MF; Sadeghi S; Mahmoudi R; Kheirollahi A; Askari H; Wickstrom SL; Poortahmasebi V; Lundqvist A; Kiessling R; Cid-Arregui A
Letter: NATURE MEDICINE. 2020;26(7):992-994
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal
Tamborero D; Dienstmann R; Rachid MH; Boekel J; Baird R; Brana I; De Petris L; Yachnin J; Massard C; Opdam FL; Schlenk R; Vernieri C; Garralda E; Masucci M; Villalobos X; Chavarria E; Calvo F; Frohling S; Eggermont A; Apolone G; Voest EE; Caldas C; Tabernero J; Ernberg I; Rodon J; Lehtio J
Review: CANCERS. 2019;11(7):E1040-1040
Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
Chen Z; Yang Y; Liu LL; Lundqvist A
Meeting abstract: CANCER IMMUNOLOGY RESEARCH. 2018;6(9):a77
Cripto-1 vaccination elicits protective immune response to metastatic breast cancer and breast cancer stem cells
Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Tufvesson-Stiller H; Ostling J; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Review: FRONTIERS IN IMMUNOLOGY. 2018;9:2159
The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment
Susek KH; Karvouni M; Alici E; Lundqvist A
Corrigendum: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2017;5(1):88
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma (vol 5, 73, 2017)
Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colon E; Scherman-Plogell A-H; Lundqvist A
Editorial comment: CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY. 2017;92(2):98-99
"Markers and Function of Human NK Cells in Normal and Pathological Conditions."
Lundqvist A; Kremer V
Meeting abstract: CANCER IMMUNOLOGY RESEARCH. 2016;4(1):b071
Enhanced IL-12 production and T cell stimulation ability by dendritic cells matured in presence of GMP-grade Toll-like receptor ligands and IFN-γ
Adamson L; Sarhan D; Choudhary B; Mellef J; Nystrom M; Edback U; Vermeij R; Scurti G; Nishimura M; Lundqvist A; Kiessling R; Lovgren T
Book chapter: DEVELOPMENTS IN T CELL BASED CANCER IMMUNOTHERAPIES: CANCER DRUG DISCOVERY AND DEVELOPMENT. 2015;p. 211-229
T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy
Masucci GV; De Petris L; Lundqvist A; Kiessling R; Lewensohn R
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2014;15(10):18557-18573
Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System
Sarhan D; D'Arcy P; Lundqvist A
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):tps3118
A phase I study of adoptive T-cell therapy with or without dendritic cell vaccination in patients with metastatic melanoma.
Tell R; Mattson J; Adamson L; Poschke I; Engstrom M; Lovpren T; Hansson J; Masuccl GV; Lundqvist A; Kiessling R
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2013;11:247
HLA-dependent tumour development: a role for tumour associate macrophages?
Marchesi M; Andersson E; Villabona L; Seliger B; Lundqvist A; Kiessling R; Masucci GV
Meeting abstract: CANCER RESEARCH. 2013;73:a15
IFN-gamma-inducible-protein-10 stimulates intratumoral infiltration of adoptively transferred human NK cells in a melanoma xenograft mouse model.
Wennerberg E; Kremer V; Lundqvist A
Meeting abstract: CANCER RESEARCH. 2013;73:a63
Melanoma-educated CD14+monocytes become myeloid-derived suppressor cell-like and are potent inhibitors of autologous T cells through Cox-2 production and STAT-3 signaling.
Mao Y; Poschke I; de Coana YP; Wennerberg E; Lundqvist A; Kiessling R
Review: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:205
Cancer classification using the Immunoscore: a worldwide task force
Galon J; Pages F; Marincola FM; Angell HK; Thurin M; Lugli A; Zlobec I; Berger A; Bifulco C; Botti G; Tatangelo F; Britten CM; Kreiter S; Chouchane L; Delrio P; Arndt H; Asslaber M; Maio M; Masucci GV; Mihm M; Vidal-Vanaclocha F; Allison JP; Gnjatic S; Hakansson L; Huber C; Singh-Jasuja H; Ottensmeier C; Zwierzina H; Laghi L; Grizzi F; Ohashi PS; Shaw PA; Clarke BA; Wouters BG; Kawakami Y; Hazama S; Okuno K; Wang E; O'Donnell-Tormey J; Lagorce C; Pawelec G; Nishimura MI; Hawkins R; Lapointe R; Lundqvist A; Khleif SN; Ogino S; Gibbs P; Waring P; Sato N; Torigoe T; Itoh K; Patel PS; Shukla SN; Palmqvist R; Nagtegaal ID; Wang Y; D'Arrigo C; Kopetz S; Sinicrope FA; Trinchieri G; Gajewski TF; Ascierto PA; Fox BA
Editorial comment: ONCOIMMUNOLOGY. 2012;1(7):1200-1201
Opposing consequences of signaling through EGF family members Escape from CTLs could be a bait for NK cells
Kiessling R; Okita R; Mougiakakos D; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kono K
Editorial comment: JOURNAL OF TRANSLATIONAL MEDICINE. 2012;10:104
Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
Masucci GV; Wersall P; Kiessling R; Lundqvist A; Lewensohn R
Other: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2012;61(4):587-591
First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.
Choudhury A; Höglund P; Kiessling R; Kärre K; Lundqvist A; Malmberg K; Mellstedt H; Scheynius A; Winqvist O; Osterborg A
Meeting abstract: BLOOD. 2011;118(21):457-458
A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity
Reger RN; Berg M; Lundqvist A; Donohue T; Carlsten M; Betters DM; Cook L; Ramos C; Grasmeder S; Su S; Stroncek D; Pantin J; Keyvanfar K; Carvallo CA; Khuu H; Childs R
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2011;47:S331
HER2-HER3 Signaling Pathway Regulates NK Cell-mediated Cytotoxicity via MHC Class I-related Chain A/ B in Human Breast Cancer Cells
Okita R; Ando T; Mougiakakos D; Mao Y; Lundqvist A; Kiessling R
Editorial comment: BLOOD. 2011;117(26):6974-6975
Unlicensed natural born killers
Lundqvist A; Childs R
Letter: BLOOD. 2010;116(15):2858-2859
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation
Yokoyama H; Lundqvist A; Su S; Childs R
Meeting abstract: CANCER RESEARCH. 2010;70:1271
In vitro expanded natural killer (NK) cells are more susceptible to Fas-mediated apoptosis compared to fresh and overnight IL-2 activated NK cells
Betters DM; Smith AL; Berg M; Lundqvist A; Childs RW
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):126-127
BORTEZOMIB TREATMENT OF PRIMITIVE QUIESCENT CD34+CELL S IN CHRONIC MYELOID LEUKEMIA ENHANCES TARGETING BY IN VITRO EXPANDED ALLOGENEIC NATURAL KILLER CELL S
Yong ASM; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):9-10
NATURAL KILLER (NK) CELLS ARE RESISTANT TO THE APOPTOTIC EFFECTS OF CORTICOSTEROIDS COMPARED TO T CELLS: IMPLICATIONS FOR ADOPTIVE NK CELL THERAPY FOLLOWING ALLOGENEIC HCT
Ramanathan M; Lundqvist A; Yokoyama H; Smith A; Childs R
Corrigendum: JOURNAL OF CLINICAL INVESTIGATION. 2008;118(4):1584
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells (vol 118, pg 1099, 2008)
Takahashi Y; Harashima N; Kajigaya S; Yokoyama H; Cherkasova E; Mccoy JP; Hanada K-I; Mena O; Kurlander R; Tawab A; Srinivasan R; Lundqvist A; Malinzak E; Geller N; Lerman MI; Childs RW
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(2):142
CYCLOSPORINE A (CSA) SIGNIFICANTLY REDUCES THE CYTOTOXIC EFFECTS OF IN VITRO EXPANDED NK CELLS: IMPLICATIONS FOR ADON TIVE NK CELL THERAPY IN THE SETTING OF ALLOGENEIC HEMATOPOIETIC STEM CELL (HCT) TRANSPLANTATION
Yokoyama H; Berg M; Lundqvist A; McCoy JP; Srivastava S; Smith A; Childs R
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(2):43
LENALIDOMIDE DIRECTLY UPREGULATES NK (NATURAL KILLER) CELL TRAIL AND GRANZYME B EXPRESSION: IMPLICATIONS FOR ADOPTIVE NK CELL IMMUNOTHERAPY FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT)
Srivastava S; Lundqvist A; Berg M; Yokoyama H; Smith A; McCoy JP; Childs R
Meeting abstract: BLOOD. 2007;110(11):4899
Cyclosporine a (CSA) significantly reduces the cytotoxic effects of in vitro expanded NK cells: Implications for adoptive NK cell therapy in the setting of allogeneic hematopoietic stem cell transplantation (HCT)
Yokoyama H; Berg M; Lundqvist A; McCoy JP; Srivastava S; Smith A; Childs R
Meeting abstract: BLOOD. 2007;110(11):3277
Significant alterations in T-Cell TH1 and TH2 cytokine gene profiles associated with G-CSF mobilization do not occur in T-Cells mobilized with AMD3100
Smith AL; Jungnam J; Rao S; Lundqvist A; Cook LW; Goodwin RS; Ramos C; Geller NL; Childs RW
Meeting abstract: BLOOD. 2007;110(11):2744
In vitro-expanded NK cells have increased TRAIL and NKG2D expression and enhanced TRAIL-mediated tumor cytotoxicity compared to non-expanded NK cells
Berg M; Lundqvist A; Fan Y; McCoy JP; Yokoyama H; Childs R
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2007;136(6):859-860
Nephrotic syndrome associated with thrombotic microangiopathy following allogeneic stem cell transplantation for myelodysplastic syndrome -: response to Nakamura et al
Srinivasan R; Balow JE; Sabnis S; Lundqvist A; Igarashi T; Takahashi Y; Austin H; Tisdale J; Barrett J; Srivastava S; Savani B; Geller N; Childs R
Meeting abstract: BLOOD. 2006;108(11):923A
Adoptive infusion of alloreactive donor NK cells reduces GVHD, mediates anti-tumor effects and prolongs survival in recipients of MHC-Matched hematopoietic cell transplantation.
Lundqvist A; McCoy P; Samsel L; Smith A; Srivastava S; Harashima N; Yokoyama H; Berg M; Childs R
Meeting abstract: BLOOD. 2006;108(11):323
Impact of KIR and HLA genotypes on outcome in nonmyeloablative hematopoietic cell transplantation (HCT) using HLA matched related donors.
Srinivasan R; Carrington M; Suffredini D; Smith A; Martin M; Berg M; Barrett AJ; Srivastava S; Lundqvist A; Yokoyoma H; Savani BN; Childs RW
Meeting abstract: BLOOD. 2006;108(11):2981
Pre-transplant T-cell lymphopenia accelerates early donor T-cell and myeloid chimerism but is not required for full donor lymphohematopoietic engraftment or to prevent graft rejection following nonmyeloabladve hematopoietic cell transplantation (NST).
Srivastava S; Savani BN; Geller N; Carvallo C; Srinivasan R; Takahashi Y; Lundqvist A; Kurlander R; Goodwin R; Barrett AJ; Fleisher T; Childs RW
Review: JOURNAL OF IMMUNOTHERAPY. 2005;28(4):281-288
Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors - Current status and future directions
Lundqvist A; Childs R
Meeting abstract: BLOOD. 2004;104(11):327B
Potent graft-versus-renal cell carcinoma (RCC) effects in a murine minor histocompatibility antigen (mHa)-mismatched allogeneic transplant model.
Lundqvist A; Srinivasan R; Suffredini D; Takahashi Y; Wynberg J; Igarashi T; Reese A; Shlomchik W; Childs R
Meeting abstract: BLOOD. 2004;104(11):811
The graft-vs-host hematopoietic effect generated after nonmyeloablative allogeneic stem cell transplantation (NST) cures patients with severe PNH
Takahashi Y; Chakrabarti S; Srinivasan R; Igarashi T; Lundqvist A; Espinoza I; Suffredini D; McCoy JP; Barrett AJ; Young NS; Childs R
Meeting abstract: BLOOD. 2004;104(11):4985
Complex alterations in serum cytokines and increased IL-4 levels characterize patients developing chronic thrombocytopenia after allogeneic hematopoietic cell transplantation.
Elshal M; Takahashi Y; Chakrabarti S; Srinivasan R; Suffredini D; Igarashi T; Solomon S; Lundqvist A; Barrett AJ; McCoy JP; Childs R
Thesis / dissertation: 2003
Dendritic cells in immune and gene therapy against cancer
Lundqvist, Andreas
Editorial comment: TRENDS IN IMMUNOLOGY. 2002;23(3):130-135
Heat-shock proteins as activators of the innate immune system
Wallin RPA; Lundqvist A; Moré SH; von Bonin A; Kiessling R; Ljunggren HG
Review: MEDICAL ONCOLOGY. 2002;19(4):197-211
Gene-modified dendritic cells for immunotherapy against cancer
Lundqvist A; Pisa P
Visa fler

Forskningsbidrag

The Swedish Childhood Cancer Fund
1 January 2024 - 31 December 2025
Regulatory properties of NK cells in solid tumors
Swedish Research Council
1 January 2023 - 31 December 2026
The Swedish Cancer Society
1 January 2022 - 31 December 2024
The Cancer Research Funds of Radiumhemmet
1 January 2022 - 31 December 2024

Anställningar

Professor, Onkologi-Patologi, Karolinska Institutet, 2023-

Examina och utbildning

MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 2003

Om mig

Forskningsbeskrivning

Undervisning

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI